| 000 | 01739 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513174602.0 | ||
| 264 | 0 | _c19990413 | |
| 008 | 199904s 0 0 eng d | ||
| 022 | _a0028-4793 | ||
| 024 | 7 |
_a10.1056/NEJM199904083401402 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMartin, D F | |
| 245 | 0 | 0 |
_aOral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. _h[electronic resource] |
| 260 |
_bThe New England journal of medicine _cApr 1999 |
||
| 300 |
_a1063-70 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAIDS-Related Opportunistic Infections _xdrug therapy |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCytomegalovirus Infections _xepidemiology |
| 650 | 0 | 4 |
_aCytomegalovirus Retinitis _xdrug therapy |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDrug Implants |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGanciclovir _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aProtease Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 |
_aSarcoma, Kaposi _xepidemiology |
| 650 | 0 | 4 | _aSurvival Analysis |
| 700 | 1 | _aKuppermann, B D | |
| 700 | 1 | _aWolitz, R A | |
| 700 | 1 | _aPalestine, A G | |
| 700 | 1 | _aLi, H | |
| 700 | 1 | _aRobinson, C A | |
| 773 | 0 |
_tThe New England journal of medicine _gvol. 340 _gno. 14 _gp. 1063-70 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1056/NEJM199904083401402 _zAvailable from publisher's website |
| 999 |
_c10153654 _d10153654 |
||